Back to GetFilings.com



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

          For the quarterly period ended September 30, 2004.

OR

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

          For The Transiton Period From __________To __________.

COMMISSION FILE NUMBER 0-19271

IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE 01-0393723
(State of incorporation)
  (IRS Employer Identification No.)
 
One IDEXX Drive, Westbrook, Maine   04092  
(Address of principal executive offices)   (ZIP Code)  
 

207-856-0300

(Registrant’s telephone number, including area code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

        Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes [X] No [  ]

        Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

        As of October 29, 2004, 33,650,985 shares of the registrant’s Common Stock, $.10 par value, were outstanding.

1


IDEXX LABORATORIES, INC. AND SUBSIDIARIES

INDEX

PART I       FINANCIAL INFORMATION   Page  
               
   Item 1.  Financial Statements     
               
      Consolidated Balance Sheets as of September 30, 2004 and     
          December 31, 2003  3  
               
      Consolidated Statements of Operations for the three and nine months     
          ended September 30, 2004 and 2003  4  
               
      Consolidated Statements of Cash Flows for the nine months     
          ended September 30, 2004 and 2003  5  
               
      Notes to Consolidated Financial Statements  6  
               
   Item 2.  Management's Discussion and Analysis of Financial Condition     
          and Results of Operations  12  
               
   Item 3.  Quantitative and Qualitative Disclosures About Market Risk  25  
               
   Item 4.  Controls and Procedures  26  
               
PART II      OTHER INFORMATION  
               
               
   Item 2.  Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities  26  
               
   Item 6.  Exhibits  27  
               
SIGNATURES         28  
               
 

2


PART I FINANCIAL INFORMATION
Item 1. Financial Statements

IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(Unaudited)

September 30, December 31,
2004
2003
        ASSETS                
Current Assets:            
     Cash and cash equivalents   $ 146,534   $ 186,717  
     Short-term investments    50,040    33,988  
     Accounts receivable, less reserves of $1,465 and $1,950 in 2004 and 2003,            
          respectively    57,950    53,976  
     Inventories    85,998    75,333  
     Deferred income taxes    13,860    13,775  
     Other current assets    6,038    6,800  


        Total current assets    360,420    370,589  


Long-term Investments    18,386    35,082  


Property and Equipment, at cost:                
     Land    2,169    1,202  
     Buildings    5,225    5,213  
     Leasehold improvements    31,610    23,139  
     Machinery and equipment    50,317    44,843  
     Office furniture and equipment    37,828    34,802  
     Construction in progress    5,392    2,824  


     132,541    112,023  
     Less accumulated depreciation and amortization    74,212    66,799  


     58,329    45,224  


Other Long-term Assets:                
     Goodwill and other intangible assets, net of accumulated amortization of  
          $36,114 and $35,451 for 2004 and 2003, respectively    69,663    61,766  
     Other noncurrent assets, net    5,606    9,214  


     75,269    70,980  


        Total Assets   $ 512,404   $ 521,875  


        LIABILITIES AND STOCKHOLDERS' EQUITY              
Current Liabilities:            
     Accounts payable   $ 18,786   $ 19,160  
     Accrued expenses    15,270    21,521  
     Accrued employee compensation and related expenses    21,087    20,792  
     Accrued taxes    16,782    21,091  
     Accrued marketing and customer programs    11,241    6,762  
     Warranty and extended maintenance agreement reserves    2,626    2,250  
     Notes payable    674    494  
     Deferred revenue    7,511    8,275  


        Total current liabilities    93,977    100,345  


Long-term Liabilities:                
     Deferred tax liabilities    1,503    236  
     Notes payable    500    --  
     Warranty and extended maintenance agreement reserves    993    1,444  
     Deferred revenue    6,231    5,772  


        Total long-term liabilities    9,227    7,452  


Commitments and Contingencies (Note 7):            
Partner's Interest in Consolidated Subsidiary    471    786  


Stockholders' Equity:                
     Common stock, $0.10 par value; Authorized: 60,000 shares; Issued: 45,155  
          and 44,390 shares in 2004 and 2003, respectively    4,516    4,439  
     Additional paid-in capital    408,509    383,249  
     Deferred equity-based compensation; Issued: 13 and 3 units in 2004            
          and 2003, respectively    620    138  
     Retained earnings    301,747    240,350  
     Accumulated other comprehensive income    6,477    4,565  
     Treasury stock (11,440 and 9,711 shares in 2004 and 2003, respectively),            
          at cost    (313,140 )  (219,449 )


        Total stockholders' equity    408,729    413,292  


        TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY   $ 512,404   $ 521,875  


  

The accompanying notes are an integral part of these consolidated financial statements.

3


IDEXX LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2004
2003
2004
2003
Revenue:                            
    Product revenue   $ 99,996   $ 91,692   $ 306,026   $ 267,011  
    Service revenue    34,115    28,369    98,881    84,143  




     134,111    120,061    404,907    351,154  
Cost of Revenue:                      
    Cost of product revenue    39,899    41,665    128,178    122,495  
    Cost of service revenue    23,154    19,306    66,623    58,436  




     63,053    60,971    194,801    180,931  




    Gross profit    71,058    59,090    210,106    170,223  




Expenses:                      
    Sales and marketing    21,132    18,222    62,794    51,743  
    General and administrative    12,698    9,206    36,523    29,396  
    Research and development    8,824    8,376    26,029    24,017  




      Income from operations    28,404    23,286    84,760    65,067  
Interest income    830    734    2,315    2,188  




      Income before provision for income taxes                      
           and partner's interest    29,234    24,020    87,075    67,255  
Provision for income taxes    9,647    8,047    25,993    22,530  
Partner's interest in loss of subsidiary    109    --    315    --  




      Net income   $ 19,696   $ 15,973   $ 61,397   $ 44,725  




Earnings per Share:                      
    Basic   $ 0.58   $ 0.46   $ 1.78   $ 1.31  




    Diluted   $ 0.56   $ 0.44   $ 1.70   $ 1.25  




Weighted Average Shares Outstanding:                      
    Basic    34,050    34,408    34,467    34,109  




    Diluted    35,467    35,977    36,120